Drugs / anti-Mesothelin Car NK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03692637 | Mar 2019 → Nov 2020 | malignant epithelial tumor of ovary | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-Mesothelin Car NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03692637 ↗ |
| Action | Deplete | “thereby inducing apoptosis of tumor cells and lysis of tumor cells” NCT03692637 ↗ |
| Modality | Cell therapy | “anti-Mesothelin Car NK Cells injection” NCT03692637 ↗ |